Poly Medicure Ltd

Poly Medicure Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Poly Medicure Ltd

₹ 1,331 3.56%
11 Mar 12:13 p.m.
polymedicure.com BSE: 531768 NSE: POLYMED
About

Poly Medicure Limited is an India-based manufacturer and exporter of medical devices. The Company exports plastic medical disposables/surgical devices.[1]

Key Points

Product Portfolio
It is a medical devices company with a product portfolio comprised of 200+ SKUs of medical devices across 12 specialties including therapy, oncology, anesthesia and respiratory care, urology, gastroenterology, blood management and blood collection, surgery and wound drainage, dialysis, central venous access catheters, veterinary medical devices, and others. [1]

Website BSE NSE
  • Market Cap ₹ 13,496 Cr.
  • Current Price ₹ 1,331
  • High / Low ₹ 2,938 / 1,210
  • Stock P/E 38.3
  • Book Value ₹ 288
  • Dividend Yield 0.27 %
  • ROCE 20.1 %
  • ROE 15.8 %
  • Face Value ₹ 5.00
Edit ratios

Pros

  • Company is almost debt free.
  • Company has delivered good profit growth of 28.4% CAGR over last 5 years

Cons

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Healthcare Equipment & Supplies Medical Equipment & Supplies

Part of BSE 500 BSE Healthcare Nifty 500 BSE Allcap BSE 250 SmallCap Index

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025
285 307 321 337 340 378 385 420 424 441 403 444 494
214 224 234 253 249 282 281 305 310 321 298 329 382
Operating Profit 71 83 87 84 90 96 104 115 114 119 106 115 111
OPM % 25% 27% 27% 25% 27% 26% 27% 27% 27% 27% 26% 26% 23%
15 9 14 15 17 15 17 27 24 27 43 35 21
Interest 5 2 2 2 3 3 3 3 3 2 3 3 6
Depreciation 14 15 16 16 16 16 20 21 21 21 23 25 29
Profit before tax 67 75 83 81 88 92 98 118 113 123 123 122 98
Tax % 25% 22% 24% 23% 26% 26% 25% 26% 25% 25% 24% 25% 27%
50 59 63 62 65 68 74 87 85 92 93 92 71
EPS in Rs 5.21 6.13 6.54 6.48 6.78 7.12 7.71 8.63 8.41 9.06 9.19 9.06 7.00
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
322 390 411 454 519 610 687 785 922 1,115 1,375 1,669 1,782
246 304 323 361 397 479 520 569 707 847 1,014 1,214 1,331
Operating Profit 76 86 88 93 122 131 166 216 215 267 361 455 451
OPM % 24% 22% 21% 21% 23% 22% 24% 28% 23% 24% 26% 27% 25%
11 28 8 14 16 20 21 22 40 38 60 94 126
Interest 9 10 10 8 12 14 20 11 6 11 14 14 14
Depreciation 14 19 21 24 29 37 41 48 54 57 63 83 98
Profit before tax 63 85 65 75 97 100 126 180 195 237 344 453 465
Tax % 30% 27% 27% 27% 27% 35% 24% 25% 25% 25% 25% 25%
45 62 48 55 71 65 96 136 147 179 258 339 348
EPS in Rs 5.11 7.07 5.47 6.25 8.00 7.41 10.86 14.17 15.28 18.69 26.91 33.41 34.31
Dividend Payout % 20% 18% 27% 40% 25% 27% 18% 18% 16% 16% 11% 10%
Compounded Sales Growth
10 Years: 16%
5 Years: 19%
3 Years: 22%
TTM: 11%
Compounded Profit Growth
10 Years: 22%
5 Years: 28%
3 Years: 33%
TTM: 12%
Stock Price CAGR
10 Years: 24%
5 Years: 9%
3 Years: 9%
1 Year: -42%
Return on Equity
10 Years: 17%
5 Years: 16%
3 Years: 16%
Last Year: 16%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Sep 2025
Equity Capital 22 22 22 44 44 44 44 48 48 48 48 51 51
Reserves 124 174 207 227 294 337 391 918 1,040 1,194 1,422 2,715 2,868
67 79 82 101 133 161 207 137 127 149 174 180 240
73 89 76 85 94 112 126 121 163 187 215 246 429
Total Liabilities 286 364 387 457 565 654 767 1,224 1,377 1,577 1,859 3,192 3,587
123 165 182 207 265 306 363 426 488 635 867 1,084 1,439
CWIP 20 10 14 20 18 19 25 21 43 78 76 101 83
Investments 3 4 4 3 17 8 25 354 346 126 167 1,077 930
140 185 187 227 264 321 354 422 499 738 748 930 1,135
Total Assets 286 364 387 457 565 654 767 1,224 1,377 1,577 1,859 3,192 3,587

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
66 63 63 56 75 106 131 119 123 191 266 240
-58 -59 -31 -56 -88 -101 -109 -436 -85 -179 -241 -1,194
5 -6 -31 -0 16 -5 -21 317 -35 -13 -20 951
Net Cash Flow 13 -2 1 0 3 1 1 0 3 -1 5 -3

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 52 59 74 77 79 77 68 72 82 77 72 76
Inventory Days 142 148 114 194 161 186 241 217 218 237 205 233
Days Payable 101 101 76 131 96 123 142 111 115 105 89 71
Cash Conversion Cycle 94 106 111 140 144 139 166 179 185 209 188 239
Working Capital Days 20 25 35 55 71 56 42 74 81 69 54 74
ROCE % 33% 30% 26% 24% 26% 22% 25% 22% 17% 18% 24% 20%

Insights

In beta
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Number of Countries Exported To
Count ・Standalone data

Log in to view insights

Please log in to see hidden values.

Login
Number of SKUs / Product Categories
Count
Patents Granted (Cumulative)
Count
Domestic Revenue Contribution
%
R&D Expenditure (Percentage of Turnover)
% ・Standalone data

Shareholding Pattern

Numbers in percentages

2 Recently
Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
53.32% 53.32% 53.17% 53.17% 53.14% 66.02% 62.56% 62.44% 62.44% 62.44% 62.42% 62.42%
16.21% 15.61% 14.49% 14.10% 12.37% 9.91% 11.88% 12.33% 11.46% 11.41% 9.77% 9.41%
3.67% 4.25% 5.15% 5.46% 7.21% 9.34% 12.33% 11.66% 11.96% 11.72% 13.53% 13.84%
26.79% 26.82% 27.20% 27.28% 27.25% 14.72% 13.23% 13.57% 14.13% 14.43% 14.28% 14.34%
No. of Shareholders 35,39336,14134,64936,05336,71236,85238,35260,68665,58371,14264,40067,750

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls